The role of growth hormone in the pathogenesis of diabetic kidney disease

Pediatric Endocrinology Reviews

Volumn 1, Issue SUPPL. 3, 2004, Pages 525-529

  Flyvbjerg, Allan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Experimental diabetes; GH antagonist; Insulin like growth factors; Mouse; Rat; Somatostatin analogue

Indexed keywords

AMINOGUANIDINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH HORMONE; GROWTH HORMONE ANTAGONIST; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; HORMONE ANTAGONIST; OCTREOTIDE; PTR 3173; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIABETIC NEPHROPATHY; GENE DISRUPTION; HUMAN; KIDNEY HYPERTROPHY; KIDNEY INJURY; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS;

ANIMALS; DIABETIC NEPHROPATHIES; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OCTREOTIDE; POLYETHYLENE GLYCOLS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 13444309578     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Deckert T, Pousen JE, Larsfin M. Prognosis of diabetics with diabetes onset before age thirty one. Diabetologia 1978;14:363-370
2. Mogensen E, Christensen CK. Predicting diabetic nephropathy in insulin dependent diabetes mellitus. N Engl J Med 1984;311:89-93
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. McNeill JH (Ed). Experimental models of diabetes. CRC Press LLC, Boca Raton, Florida, USA, 1999; pp. 1-418
6. Young FG. Permanent diabetes produced by pituitary (anterior lobe) injections. Lancet 1937;ii:372-374
7. Campbell J, Davidson IWF, Lei HP. The production of permanent diabetes by highly purified growth hormone. Endocrinology 1950;46:588-590
8. Yde H. Abnormal growth hormone response to ingestion of glucose in juvenile diabetics. Acta Med Scand 1969;186:499-504
9. Hansen AaP, Johansen K. Diurnal pattern of blood glucose, serum FFA, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970;6:27-33
10. Lundbœk K, Christensen HJ, Jensen VA, Johansen K, Olsen TS, Hansen AaP, Ørskov H, Østerby R. Diabetes, diabetic angiopathy and growth hormone (hypothesis). Lancet 1970;ii:131-133
11. Yde H. The growth hormone dependent sulphation factor in serum from patients with various types of diabetes. Acta Med Scand 1969;186:293-297
12. Ftyvbjers A. Growth factors and diabetic complications. Diabetic Med 1990;7:387-399
13. Janssen JAMJL, Lamberts SWJ. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 2000;52:1-9
14. Møller N, Ørskov H. Growth hormone, IGF-I and diabetic angiopathy revisited. Clin Endocrinol 2000;52:11-12
15. Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signalling. Oncogene 2000;19:2585-2597
16. Frank SJ. Growth hormone signalling and its regulation: preventing too much of a good thing. Growth Horm IGF Res 2001;11:201-212
17. Finidori J. Regulators of growth hormone signalling. Vitam Horm 2000;59:71-97
18. Hwa V, Oh Y, Rosenfeld RC. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999;20:761-787
19. Pankov YA. Growth hormone and a partial mediator of its biological action, insulin-like growth factor I. Biochemistry (Masc) 1999;64:1-7
20. LeRoith D. Insulin-like growth factor I receptor signalling-overlapping or redundant pathways? Endocrinology 2000;141:1287-1288
21. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997;8:45-62
22. Shimasaki S, Shimonaka M, Zhang HP, Ling N. Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem 1991;266:10646-10653
23. Shimasaki S, Gao L, Shimonaka M, Ling N. Isolation and molecular cloning of insulin-like growth factor-binding protein-6. Mol Endocrinol 1999;5:938-948
24. Flyvbjers A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000;43:1205-1223
25. Conti FG, Striker U, Elliot SJ, Andreani D, Striker GE. Synthesis and release of insulin-like growth factor I by mesangial cells in culture. Am J Physiol 1988;255:F1214-F1219
26. Conti FG, Striker LJ, Lesniak MA, MacKay K, Roth J, Striker GE. Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells. Endocrinology 1988;122:2788-2795
27. Doi T, Striker LJ, Elliot SJ, Conti FG, Striker GE. Insulin-like growth factor-1 is a progression factor for human mesangial cells. Am J Pathol 1989;134:395-404
28. Conti FG, Elliot SJ, Striker LJ, Striker GE. Binding of insulin-like growth factor-i by glomerular endothelial and epithelial cells: further evidence for IGF-I action in the renal glomerulus. Biochem Biophys Res Commun 1989;163:952-958
29. Schreiber BD, Hughes ML, Groggel GC. Insulin-like growth factor-1 stimulates production of mesangial cell matrix components. Clin Nephrol 1995;43:368-374
30. Moran A, Brown DM, Kim Y, Klein DJ. Effects of IGF-I and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture. Diabetes 1991;40:1346-1354
31. Tack I, Elliot SJ, Potier M, Rivera A, Striker GE, Striker LJ. Autocrine activation of the IGF-I signalling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes 2002;51:182-188
32. Oemar BS, Foellmer HG, Hodgdon-Anandant L, Rosenzweig SA. Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J Biol Chem 1991;266:2369-2373
33. Flyvbjerg A, Frystyk J, Østerby R, Ørskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Physiol 1992;262:E956-E962
34. Grønbœk H, Volmers P, Bjorn SF, Østerby R, Ørskov H, Flyvbjerg A. Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats. Am J Physiol 1997;272:E918-E924
35. Grønbœk H, Nielsen B, Schrijvers B, Vogel I, Rasch R, Flyvbjerg A. Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. J Endocrinol 2002;172:637-643
36. Landau D, Segev Y, Afargan M, Silbergeld A, Katchko L, Podshyvatov A, Phillip M. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int 2001;60:505-512
37. Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 1990;87:5061-5065
38. Chen WY, White ME, Wagner TE, Kopchick JJ. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analogue results in dwarf transgenic mice. Endocrinology 1991;129:1402-1408
39. Chen N-Y, Chen WY, Bellush L, Yang C-W, Striker LJ, Striker GE, Kopchick JJ. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995;136:660-667
40. Chen N-Y, Chen WY, Kopchick JJ. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 1996;137:5163-5165
41. Bellush LL, Doublier S, Holland AN, Striker U, Striker GE, Kopchick JJ. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 2000;141:163-168
42. Flyvbjers A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999;48:377-382
43. Segev Y, Landau D, Rasch R, Flyvbjers A, Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 1999;10:2374-2381
44. Flyvbjers A, Rasch R. Effect of growth hormone (GH) receptor antagonist (G120K-PEG) treatment on manifest renal changes in non obese diabetic (NOD) mice [Abstract]. J Am Soc Nephrol 1999;10:A3443
45. Nilsson AB, Nitescu N, Chen Y, Guron GS, Marcussen N, Matejka GL, Friberg P. IGF-I treatment attenuates renal abnormalities induced by neonatal ACE inhibition. Am J Physiol 2000;279:R1050-R1060
46. New JP, Canavan JP, Flyvbjers A, Hamon G, Bilous RW, Marshall SM. Renal enlargement and insulin-like growth factor-1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition. Diabetologia 1996;39:166-171
47. Grønbœk H, Vogel I, Østerby R, Lancranjan I, Flyvbjers A, Ørskov H. Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. Kidney Int 1998;53:173-180
48. Bach LA, Dean R, Youssef S, Cooper ME. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol Dial Transplant 2000;15:347-354